The cannabis industry is on the cusp of a pivotal transformation with the potential rescheduling of cannabis from Schedule I to Schedule III. This groundbreaking change would signal a major shift in federal policy, bringing significant implications for businesses, regulations, and the broader industry landscape.

Denise Pollicella, Chair of the Cannabis Law Practice at Omnus Law, recently shared her insights with Benzinga, offering expert analysis on how this change could shape the future of cannabis regulation.

Key Insights from the Interview

  • FDA Oversight and Compliance
    Pollicella emphasized that the transition to Schedule III would bring cannabis under FDA oversight, creating new challenges for businesses. Companies would face stricter production standards akin to those in the pharmaceutical industry, driving up costs in an already competitive market.
  • Interstate Commerce Potential
    The rescheduling could pave the way for interstate commerce, enabling states with mature medical cannabis markets—such as Michigan and Pennsylvania—to become leaders in supply chain innovation. This shift would fundamentally reshape how cannabis is produced, distributed, and sold across the U.S.
  • Industry Consolidation
    As businesses adapt to heightened regulatory requirements, Pollicella predicts a wave of mergers and acquisitions. Companies that prioritize scalability and strategic growth will be best positioned to thrive in this new era of compliance.

Omnus Law: Guiding Clients Through Industry Transformation

Omnus Law’s Cannabis Practice, led by Pollicella, stands ready to guide clients through this period of rapid change. With decades of experience in navigating complex regulatory landscapes, our team offers the strategic advice businesses need to remain compliant, competitive, and forward-thinking in an evolving marketplace.

Read the full article on Benzinga here